Clinical trials: Carcinoma, Transitional Cell
Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
This phase II trial compares the effect of adding radiation therapy to an immunotherapy drug called pembrolizumab versus pembrolizumab alone in treating patients with urothelial cancer that has spread from where it first started…
- Conditions
- Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
- Trial name
- NCT04936230
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 83 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
UC (Urothelial Cancer)
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
- Trial name
- NCT02872714
- Testing
- pemigatinib
- Where
- 96 sites in United States, Belgium and 9 more
- Volunteers
- 263 people
- Sponsor
- Incyte Corporation
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy.
- Conditions
- Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra, Urothelial Carcinoma Recurrent
- Trial name
- GRAPE (NCT06983210)
- Testing
- Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy
- Where
- Japan
- Volunteers
- 43 people
- Sponsor
- Nagoya University
Melanoma, Head and Neck Cancer
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck…
- Conditions
- Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT02475213
- Testing
- Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2
- Where
- 20 sites in United States
- Volunteers
- 146 people
- Sponsor
- MacroGenics
Urothelial Carcinoma
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Urothelial carcinoma (UC) is the ninth most common cancer type worldwide. While the treatment of front-line metastatic urothelial carcinoma (mUC) has improved, there remains a high unmet need for effective therapies for…
- Trial name
- LIVIGNO-3 (NCT06632951)
- Testing
- Livmoniplimab, Budigalimab, Docetaxel
- Where
- 37 sites in United States, Canada and 6 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Bladder Cancer, Cystectomy
Supporting Sexual Recovery in Women With Bladder Cancer
This study looks at how bladder cancer and removing the bladder can affect women's sexual well-being. Bladder cancer can be more serious in women, and treatment like bladder removal can impact how they feel about themselves and…
- Conditions
- Bladder Cancer, Cystectomy, Female Sexual Dysfunction
- Trial name
- SPARC (NCT07091565)
- Testing
- Qualitative interview/Focus group
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- King's College London
Transitional Cell Bladder Cancer, Cystectomy
Radical Cystectomy Versus Tri-Modal Therapy for Treatment of cT2N0M0 Urinary Bladder Transitional Cell Carcinoma
the aim of this study is to compare the oncological outcome of trimodal therapy with bladder preservation using maximal resection with chemoradiation versus the standard radical cystectomy for muscle invasive transitional cell…
- Conditions
- Transitional Cell Bladder Cancer, Cystectomy, Radiation
- Trial name
- NCT07043790
- Testing
- Radical cystectomy with pelvic lymphadenectomy, Trimodal therapy
- Where
- Egypt
- Volunteers
- 73 people
- Sponsor
- Ain Shams University
Bladder Cancer, Urothelial Carcinoma
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
- Trial name
- NCT05524545
- Testing
- Evorpacept, Enfortumab Vedotin
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- ALX Oncology Inc.
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
The TEMPO-MIBC trial is a phase III, single-center, two-arm, randomized, controlled trial. Its primary objective is to evaluate the efficacy of a simplified diagnostic and treatment pathway for muscle-invasive bladder cancer…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy, Bladder Carcinoma, Bladder Neoplasm
- Trial name
- TEMPO-MIBC (NCT07067749)
- Testing
- multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), Circulating tumour DNA levels assessment
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- University of Rome Tor Vergata
Urothelial Carcinoma
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer.
- Trial name
- NCT05902494
- Where
- 23 sites in United States, Austria and 2 more
- Volunteers
- 389 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Locally Advanced or Metastatic Urothelial Carcinoma
Neurological Function in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin-Based Therapy
This prospective observational study aims to evaluate the correlation between neurological function and patient-reported symptoms of peripheral neuropathy (PN) in patients with locally advanced or metastatic urothelial carcinoma…
- Trial name
- NCT07072637
- Testing
- Neurological function assessment
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
This study is being conducted to establish a novel tumor tissue- and blood-based biomarker test to assess early systemic and local response to immunomodulation by BCG immunotherapy in patients with high-risk non-muscle invasive…
- Conditions
- NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder
- Trial name
- BCG-TIME (NCT07064863)
- Testing
- Gemcitabine + BCG, BCG (TICE strain)
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Queen's University
Melanoma, Breast Cancer
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with and without PD-1 blockade and with and without intratumoral poly-ICLC. A device called the Echopulse will be used for the FUSA therapy.
- Conditions
- Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer
- Trial name
- AM-003 (NCT04116320)
- Testing
- Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Craig L Slingluff, Jr
Advanced Solid Tumor, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04242199
- Testing
- INCB099280
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 182 people
- Sponsor
- Incyte Corporation
Bladder (Urothelial, Transitional Cell) Cancer
Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy
The goal of this observational study is to evaluate the safety and efficacy of neoadjuvant therapy followed by bladder - preserving TMT in patients with MIBC.
- Trial name
- NCT07053722
- Testing
- NA-TMT
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Bladder (Urothelial, Transitional Cell) Cancer
An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer
The goal of this exploratory study is to evaluate the safety and efficacy of nimotuzumab combined with chemoradiotherapy in bladder - preserving treatment for MIBC patients who are ineligible for or decline radical cystectomy.
- Trial name
- NCT07053735
- Testing
- Nimotuzumab and Radiotherapy
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Bladder Cancer
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Background: Many cancers produce two particular proteins. The immune system can target these to attack the cancer. The PANVAC vaccine puts genes for these proteins inside a virus vaccine so the body sees the proteins as foreign…
- Trial name
- NCT02015104
- Testing
- BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
This is a single-arm, phase 1/2a study of formulated paclitaxel in subjects with low-grade, noninvasive papillary carcinoma (stage Ta) of the bladder.
- Conditions
- Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder
- Trial name
- NCT03081858
- Testing
- TSD-001
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lipac Oncology LLC